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DNAvaccines and recombinant Listeria monocytogenes that express and secrete SIV Gag and Env antigens were combined in a nonhuman
primate prime-boost immunogenicity study followed by a challenge with SIV239. We report that recombinant DNA vaccine delivered
intramuscularly, and recombinant L. monocytogenes delivered orally each individually have the ability to induce CD8+ and CD4+ T cell
immune responses in a nonhuman primate. Four rhesus monkeys were immunized at weeks 0, 4, 8, and 12 with the pCSIVgag and pCSIVenv
DNA plasmids and boosted with SIVexpressing L. monocytogenes vaccines at weeks 16, 20, and 28. Four rhesus monkeys received only the L.
monocytogenes vaccines at weeks 16, 20, and 28. A final group of monkeys served as a control group. Blood samples were taken before
vaccination and 2 weeks post each injection and analyzed by ELISPOT for CD4+ and CD8+ T cell responses. Moderate vaccine induced SIV-
specific cellular immune responses were observed following immunization with either DNA or L. monocytogenes vectors. However, the SIV
antigen-specific immune responses were significantly increased when Rhesus macaques were primed with SIV DNA vaccines and boosted
with the SIVexpressing L. monocytogenes vectors. In addition, the combined vaccine was able to impact SIV239 viral replication following an
intrarectal challenge. This study demonstrates for the first time that oral L. monocytogenes can induce a cellular immune response in a
nonhuman primate and is able to enhance the efficacy of a DNA vaccine as well as provide modest protection against SIV239 challenge.
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The importance of a CD8+ cytotoxic T lymphocyte
response in controlling HIV replication is supported by a
number of studies in humans and nonhuman primates
(Amara et al., 2001; Barouch et al., 2001; Schmitz et al.,
1999; Shiver, 2003; Shiver et al., 1995). The most efficient
means of inducing a CD8+ T cell mediated immune
response is through live infection. As such, gene-delivered05) 88–101
J.D. Boyer et al. / Virology 333 (2005) 88–101 89antigens are conceptually presented to the immune system
in a manner similar to that which occurs during natural viral
infection. The host-synthesized viral proteins are subjected
to natural immune surveillance by the exogenous and
endogenous antigen pathways resulting in both major
histocompatibility complex (MHC) class I- and class II-
driven cellular responses. Many of the HIV-1 vaccine
approaches that are under development (Marsac et al.,
2002; Rose et al., 2001; Seth et al., 1998, 2000; Vajdy et al.,
2001; van Loon et al., 1996; Worku et al., 2001) deliver
HIV-1 antigens to the host through recombinant viral
infection. In addition, various combinations of the different
strategies have demonstrated induction of cellular immune
responses, which can impact viral replication in the SIV
macaque model (Allen et al., 2000; Amara et al., 2001;
Hanke et al., 1999). Our laboratory and others have
demonstrated that DNA inoculation technology can be used
to develop an HIV-1 antigen-specific immune response in
mice, rhesus macaques, chimpanzees, and humans (Boyer et
al., 2000; Kim et al., 2000; MacGregor et al., 2002; Vajdy et
al., 2001; Wang et al., 1993, 1994, 1995). Furthermore,
these vaccines induce a strong Th1-biased CD8+ T cell-
mediated immune response. However, these approaches
have not, in general, used mucosal delivery schemes thought
to be important for control of lentiviral replication. We
reasoned that one useful approach would be to study the
ability of a DNA vaccine combined with a mucosal delivery
vaccine strategy to induce a cellular immune response.
Listeria monocytogenes, a gram-positive facultative
intracellular bacterium, has been developed as a live vaccine
vector (Weiskirch and Paterson, 1997). This vector induces
weak humoral responses but a strong cellular response with
both CD8+ and CD4+ T cell activation (Bishop and
Hinrichs, 1987; De Libero and Kaufmann, 1986) of the
Th1 phenotype (Hsieh et al., 1993a, 1993b; Mata and
Paterson, 1999) in mice when delivered either intraperito-
neally or orally. Earlier work described a genetic method to
modify the chromosome of L. monocytogenes so that HIV
gene products can be expressed as secreted proteins under
the control of a copy of the strong promoter of the
hemolysin (hly) gene, which encodes listeriolysin-O
(Frankel et al., 1995). A Listeria vector expressing HIV-1
Gag (Lm-HIV-Gag) was shown to induce strong cell
mediated immunity when delivered parenterally (Frankel
et al., 1995; Mata and Paterson, 1999; Mata et al., 1998,
2001) or orally (Peters et al., 2003) and to protect againstTable 1
Immunization and challenge regimen
Group Weeks 0, 4, 8, 12 Weeks 16, 20
1 DNA
2 mg SIVgag
2 mg SIVenv
L. monocytogenes gag and
env vectors oral 3  1010/dose
2 – L. monocytogenes gag and
env vectors oral 3  1010/dose
Control – –challenge with vaccinia virus expressing Gag in two strains
of mice (Mata et al., 2001). However, L. monocytogenes-
based vaccines for HIV or SIV antigens have not been
examined previously in a nonhuman primate model.
Accordingly, we studied these two methods of vacci-
nation, oral recombinant Listeria monocytogenes-based
vaccines and intra-muscular DNA plasmid vectors, alone
and in a prime-boost strategy. We focused on using two
SIV antigens, Gag and Env. Three L. monocytogenes
vaccines were constructed that expressed and secreted
SIV Gag, a fragment of SIV Env that spanned residues
30 to 298 and a fragment of SIV Env that spanned 198 to
525. SIV-specific cellular immune responses were assessed
by IFN-g ELISpot in peripheral blood 2 weeks following
each immunization with the DNA and L. monocytogenes
vectors separately, and together, in Chinese Rhesus
macaques. The immunization schedule is shown in Table
1. Although all the immunization strategies, we tested
induced cell mediated immunity, as determined by ELIspot
analysis, the SIV antigen-specific immune responses were
significantly improved when the macaques were primed
with SIV DNA vaccines and boosted with the SIV-
expressing L. monocytogenes vectors delivered orally. To
test whether levels of cellular immunity observed translated
into protective levels of immunity, we challenged the
animals intrarectally with a high challenge dose of
SIV239mac 8 weeks following the last immunization. All
monkeys did become infected following viral challenge.
The monkeys that received DNA and were boosted with
recombinant Listeria controlled viral load for a significantly
longer period of time compared to the group that received
recombinant Listeria and the control group. In addition, no
significant latent virus levels were detected in resting CD4+
T cells from the animals in the group that controlled viral
load or in their inguinal lymph nodes.Results
Chemistry and hematology safety studies following
immunization with DNA and L. monocytogenes
The immunization schedule is shown in Table 1. Animals
received four DNA vaccines followed by three L. mono-
cytogenes boosts. All animals appeared in good health
throughout the study as assessed by body weights andWeek 28 Week 36
L. monocytogenes gag and
env vectors oral 6  1010/dose
2500 TCID50 SIV239
L. monocytogenes gag and
env vectors oral 6  1010/dose
2500 TCID50 SIV239
– 2500 TCID50 SIV239
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blood 2 weeks following each immunization. The animals
did not suffer from any diarrhea or lethargy following
immunization with Listeria and prior to challenge with
SIV239. The liver can also be a site affected by systemic
Listeria infection. Liver function is assessed by alkaline
phosphatase and gamma glutamyl transaminase levels. The
normal ranges for these two proteins are 120.5–1053 U/l
and 24.4–108.9 U/l, respectively. In addition, a high mean
corpuscular volume (MCV) is associated with liver disease,
normal range is approximately 66–80 fl. All values
remained within normal ranges. These results confirm there
are no consistent pathological abnormalities observed as
consequences of either SIV DNA vaccination, recombinant
L. monocytogenes vaccination or a combination of the two
vaccines in the prime/boost strategy.
Cellular immune response to SIV Gag and SIV Env
following immunization with L. monocytogenes
We assessed the ability of recombinant L. monocyto-
genes vaccines expressing SIV antigens to induce a cellular
immune response following oral inoculation of rhesus
macaques. Animals were bled prior to, and 2 weeks
following, each immunization (Table 1). PBMCs were
isolated and incubated with SIV Gag peptide mix or SIV
Env peptide mix overnight. The number of cells secreting
IFN-g in a Gag- or Env-specific manner was determined
using a standard ELISpot assay. The results are presented in
Figs. 1C and D, respectively. There were no significant
responses observed following one immunization to either
Gag or Env peptide pools. However, following two
immunizations with recombinant L. monocytogenes 2 of 4Table 2
Clinical tests performed to determine safety of DNA and L. monocytogenes
immunization of rhesus macaques
Clinical chemistry values Clinical hematology labs
Calcium Platelets
Phosphate White blood cells
Glucose Hemoglobin
Blood urea nitrogen Hematocrit
Creatine Mean corpuscular volume
Protein Mean corpuscular hemoglobin
Albumin Mean corpuscular
hemoglobin concentration
Globulin Segmented neutrophils
Albumin/Globulin ratio Band neutrophils
Total bilirubin Absolute band count
Alanine aminotransferase Monocytes
Alkaline phosphatase Eosinophils
Aspartate aminotransferase Basophils
Sodium Atypical lymphocytes
Potassium Total lymphocytes
Chloride CD4
Cholesterol CD8
Gamma glutamyl transaminase CD4/CD8 ratio
CD3/CD8 ratio
CD3/CD4 ratiorhesus macaques responded to Gag. The mean number of
Gag-specific IFN-g secreting cells was 140 (F132) SFC per
1 million PBMCs which is statistically different to the
unimmunized controls (P b 0.05). Furthermore, following 2
immunizations 2 of 4 rhesus macaques responded to Env.
The mean number of Env-specific INF-g secreting cells was
94 (F58) SFC per 1 million PBMCs (P b 0.05 compared to
unimmunized control values). Finally, it appears that a third
and final immunization with recombinant L. monocytogenes
did not further enhance the vaccine-induced immune
response to either antigen, suggesting an anti-Listeria
response had developed that prevented vaccine boosting.
Cellular immune response to SIV Gag and SIV Env
following immunization with DNA vaccines
We also assessed the ability of rhesus macaques to
respond to DNA vaccines expressing SIV Gag or SIV Env.
The results are presented in Figs. 1E and F. Following one
immunization, no antigen-specific immune responses were
observed. However, following two immunizations 2 of 4
rhesus macaques developed an antigen response to Gag,
mean 130 (F144) SFC per 1 million PBMCs. Following the
third immunization 1 of 4 animals demonstrated an Env-
specific immune response; mean 82 (F142) SFC per
1 million PBMCs. In addition, 2 of 4 animals demonstrated
a positive response to SIV Gag, mean 180 (F182) SFC per
1 million PBMCs. However, animal 3232, which demon-
strated an immune response following the second injection,
did not demonstrate an immune response following the third
or fourth immunization. Animal 3233 demonstrated a Gag-
specific response following the third immunization, which
was sustained following each subsequent immunization.
Rhesus macaque 3239 which demonstrated an immune
response to Gag following the second immunization had an
immune response, which was sustained following each
immunization. The mean number of INF-g-producing cells
following the fourth immunization in this nonhuman
primate group was 153 (F123) SFC per 1 million PBMCs
for Gag, and 50 (F78) SFC per 1 million PBMCs for Env.
The response rates were, however, 2/4 for Gag and 1/4 for
Env.
Cellular immune responses to DNA vaccines are boosted by
recombinant L. monocytogenes-expressing SIV antigens
We next examined if L. monocytogenes would boost a
DNA vaccine primed cellular immune response to the SIV
antigens. As noted above, the mean number of INF-g-
producing cells following the final DNA immunization was
153 (F123) SFC per 1 million PBMCs for Gag, and 50
(F78) SFC per 1 million PBMCs for Env. These numbers
were not significantly increased following the first boost
with L. monocytogenes. However, following the second
boost with L. monocytogenes, the response to Gag was 603
SFC per 1 million (F268), Fig. 2A (P b 0.05). Following
Fig. 1. IFN-g-producing cells following immunization with either a Listeria monocytogenes vaccine or a DNA vaccine. Samples were taken before vaccination
and 2 weeks post each injection. PBMCs were isolated by a standard ficoll-hypaque separation technique and assessed for a Gag antigen-specific response or an
Env antigen-specific response by a standard ELISPOT. The top two panels show responses in control rhesus monkeys to (A) Gag and (B) Env. The middle two
panels show responses in L. monocytogenes SIV immunized animals, after 1, 2, and 3 immunizations, to (C) Gag and (D) Env. The bottom two panels show
responses in DNA immunized animals, after 1, 2, 3, and 4 immunizations, to (E) Gag and (F) Env.
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Env was 286 (F52), Fig. 2B (P b 0.05). In addition, 4 of 4
animals responded to both the Env and Gag antigens
following the DNA prime and two boosts of recombinant L.
monocytogenes. As observed earlier, a third and final boost
with L. monocytogenes did not appear to enhance the
immune response beyond what was seen following two
immunizations with L. monocytogenes. This suggests that
the L. monocytogenes vector induced an immune response
against its own antigens that limited further boosting against
the encoded SIV passenger antigens.
CD8+ T cell immune responses to DNA vaccines are boosted
by recombinant L. monocytogenes expressing SIV antigens
To assess if the cells secreting INF-g were CD8+ or CD4+
lymphocytes we depleted PBMCs of CD8+ T cells using
magnetic beads coated with anti-CD8 monoclonal antibody
(Dynal) and set up the remaining cells in a standard ELISpot
assay. The immune response 2 weeks post the second L.monocytogenes boost is presented in Fig. 3 for individual
macaques. It is clear that a CD8+ SIV-specific immune
response was induced to both the Env (Fig. 3C) as well as the
Gag (Fig. 3D) antigens. The average Env-specific response
prior to CD8+ T cell depletion was 286 SFC/million PBMCs
(F52 SFC/million PBMCs). However, following CD8+ Tcell
depletion, the average Env-specific response was almost
completely eliminated (P = 0.0679). The average CD8+ Tcell
immune response to Gag prior to depletion was 603 SFC/
million PBMCs (F268 SFC/million PBMCs), which de-
creased to 248 SFC/million PBMCs (F126 SFC/million
PBMCs) following CD8+ T cell depletion (P = 0.0679). This
indicates a higher level of Gag antigen-specific CD4+ T cell
responses compared to the envelope responses. These trends
were observed in all animals.
Viral loads
All animals were challenged with 2500 TCID50 of
SIV239 8 weeks after the last immunization. Data presented
Fig. 2. SIV Gag- and Env-specific IFN-g producing cells following DNA immunization and a boost with recombinant L. monocytogenes vaccine. PBMCs
from control animals and animals immunized with pCSIVgag and pCSIVenv DNA plasmids followed by a boost with the L. monocytogenes vaccines were
tested for their ability to respond in vitro to SIV Gag (A) or to SIV Env (B). PBMCs were isolated and were aliquoted at a concentration of 200,000 cells per
well and mixed with SIV-specific peptides. The plates were incubated overnight and the number of IFN-g-producing cells was enumerated.
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level of infection in animals 3240 (Fig. 4B) and 3239 (Fig.
4D) had low levels of infection with a peak viral load about
3 logs lower than any of the animals in the control group.Fig. 3. CD8+ IFN-g-producing cells following DNA prime and L. monocytogenes v
a standard ELISPOT. PBMCs were isolated and depleted of CD8+ cells and were a
Gag-specific peptides. The plates were incubated overnight and the number of IFN
assessed with Env peptides. (B) PBMCs from control animals were assessed with G
peptides. (D) PBMCs from immunized animals were assessed with Gag peptidesThere were no statistically significant differences between
the control group (Fig. 4A) and the animals immunized with
Listeria vector alone (Fig. 4B). Although one of three
animals in the control group appeared to suppress viral load,accine boost. The CD8+ antigen-specific immune response was assessed by
liquoted at a concentration of 200,000 cells per well and mixed with Env- or
-g producing cells was enumerated. (A) PBMCs from control animals were
ag peptides. (C) PBMCs from immunized animals were assessed with Env
.
Fig. 4. Viral Loads following Challenge with SIV239. Samples were
taken before and after SIV239 intrarectal challenge. PBMCs were
isolated and viral loads were assessed by standard assays. (A) Control
animals, (B) animals immunized with L. monocytogenes expressing Gag
and Env DNA plasmids, and (C) animals immunized with pCSIVgag
and pCSIVenv DNA plasmids followed by a boost with the L.
monocytogenes vaccines.
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other animals in this study. In contrast, 3 out of 4 monkeys
that received both DNA and Listeria controlled viral load in
the blood. Following a peak viral load observed at 4 weeks
post-challenge, viral loads decreased to set-point by week
16 post-challenge and remained there till week 32, post-
challenge, at which time animal 3239 had viral break-
through suggesting that there was viral escape. However,
animals 3233 and 3234 maintained suppressed viral loads
44 weeks post-challenge. The group of animals that received
a DNA prime followed by a Listeria boost were able tocontrol viral loads for a significantly longer time period than
the control group, (P = 0.0279 by Fischer’s exact test).
Anti-SIV antibodies detection
We assessed sera for circulating anti-SIVantibodies using
an anti-HIV-2 IgG ELISA Kit (Genetic Systems, Seattle,
Wash.), which is cross-reactive for SIV antibodies. We did
not detect any antibody responses as a result of the
immunization regimens (data not shown). DNA immuniza-
tion, L. monocytogenes or the two used in combination were
unable to induce antibodies specific to SIV. This suggests
that the immune responses generated by these vaccines were
predominantly cell mediated. However, following challenge
most animals rapidly demonstrated antibody responses that
suggested that the immunized animals were primed for
antibody development, Fig. 5. The animals that were
immunized with recombinant Listeria alone clearly demon-
strated a shorter time interval to the development of peak
antibody levels. Three of four animals demonstrated a peak
between weeks 6 and 10 after challenge which was
significantly higher than control animals (P = 0.049).
Animals 3240 did not demonstrate antibody at any time
point; most likely, as Fig. 4B indicates, the level of infection
in this animal was not sufficient to recall a humoral response
and it was removed from this analysis. The control group of
animals demonstrated peak antibody levels between weeks
10 and 20 in 3 of 3 animals challenged. The antibody
responses in the DNA primed-Listeria boosted group had a
response profile following challenge that varied between
animals. Animals 3232 and 3233 had a continuing rise in
antibody levels past 15 weeks. Animal 3234 reached a
maximum response at approximately week 6, whereas
animal 3239 had a low but detectable antibody response
at the time of challenge, which was undetectable until
approximately week 26.
Viral reservoirs
We assessed the viral reservoir status in all animals that
demonstrated suppressed viral replication in two tissues.
The frequency of resting CD4+ T cells, in peripheral blood,
harboring replication competent SIV, was measured 25
weeks after challenge, Table 3. It was below the limit of
detection in animals 3239 and 3240 and was barely
detectable in animal 3233. Interestingly, these animals also
had the lowest peak viral loads as well as suppression of
viral replication. As we discussed above, 3240 did not
become highly infected. Animal 3239 eventually had viral
breakthrough demonstrating the persistence of SIV in a viral
reservoir despite suppression of viremia to below detectable
limits. Animal 3247, the macaque in the control group
which was able to control viral load, demonstrated the
highest level of infected resting CD4+ T cells, (Table 3).
We also examined inguinal lymph nodes, harvested from
monkeys that appeared to control viremia: 3247 in the
Table 3
Viral reservoir in peripheral blood and resting CD4+ T cells
Weeks post-challenge
Macaque/
vaccine
regimen
Peripheral blooda Resting
CD4+
T cellsb
3 weeks 7 weeks 11
weeks
15 to 25
weeks
25 weeks
3233
DNA/Lm
143,980 b200 b200 b200 67
3234
DNA/Lm
820,860 480 600 b200 Not done
3239
DNA/Lm
4180 1500 b200 b200 b33
3240
Lm only
1520 b200 b200 b200 b33
3247
Control
49,560 220 2760 b200 1333
a SIV DNA copy eq/ml of plasma.
b SIV DNA copies per million resting CD4+ T cells.
Fig. 5. Antibody to SIV Env. Sera was isolated at the time of challenge and
following challenge and tested in a standard HIV-2 ELISA kit for binding to
HIV-2 Env using OD units as a measure of antigen-specific responses. (A)
Control animals, (B) animals immunized with L. monocytogenes expressing
Gag and Env DNA plasmids, and (C) animals immunized with pCSIVgag
and pCSIVenv DNA plasmids followed by a boost with the L.
monocytogenes vaccines.
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vaccine group and 3240 in the group that received the
Listeria vaccines alone. Lymph nodes were harvested at the
time of sacrifice 44 weeks after viral challenge. Virus could
only be detected in sections from monkey 3247 in the
control group and 3239 where virus escape had occurred at
about 32 weeks post-infection (Fig. 6).
Clinical outcome
Infected animals were monitored for clinical symptoms
of disease and lymphocyte subsets. Euthanasia did not have
to be performed on any animals in this study. Fig. 7summarizes the CD4+ lymphocyte level as number of cells
per mm3 of blood. All animals had a decrease in CD4+ T
cell numbers following infection. However, for those
animals with the lowest viral set points, that is, 3233,
3234, and 3239 in the DNA-primed Listeria boosted group
and 3235 and 3240 in the Listeria alone group, only 3234
failed to return to normal CD4+ T cell levels. In addition,
over time the DNA-primed Listeria boosted group did not
demonstrate as significant a decrease compared to the
control group (P = 0.0087).Discussion
This is the first published study to examine the
immunization potential of oral recombinant L. monocyto-
genes expressing SIVantigens in nonhuman primates. There
are obvious advantages to immunizing with an oral vaccine.
As the most widely used mucosal vaccination route, oral
immunization has proven both practical and reliable in
large-scale public health vaccination programs and gener-
ally elicits a high level of compliance from clinical cohorts
enrolled in oral vaccine field trials (Sabin, 1985; van Loon
et al., 1996). We found that Rhesus macaques immunized
with L. monocytogenes by the oral route developed an
antigen-specific cellular immune response to both SIV-
mac239 Env and SIVmac239 Gag following two immuni-
zations with recombinant L. monocytogenes. There did not
appear to be any boosting following a third immunization. It
is possible that the immune response following this last
immunization was limited to mucosal lymphoid sites and
did not emerge in the periphery. However, more likely, the
repeated immunizations with recombinant Lm-SIV vectors
induced sufficient anti-vector immunity to interfere with the
presentation of the transgene product upon subsequent
boosts. We have recently shown that Lm-HIV-Gag is
Fig. 6. Detection of SIV virus in inguinal lymph nodes by in situ hybridization. Lymph nodes were harvested at 44 weeks post-intrarectal challenge with
SIV239. Multiple sections were cut and examined for the presence of virus (see arrows). Typical views are shown at 10-fold magnification for macaques 3233,
3240 and 3239. 3247 is shown at a magnification of 20-fold. The viral load (VL) in peripheral blood at the time of sacrifice is shown on the figure for
comparison.
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a second oral immunization, although immune boosting was
achieved (Peters et al., 2003). A lack of subsequent boosting
after repeated immunization has been observed in other
recombinant vaccine systems. In fact, a CTL response to
SIV Gag was not further enhanced by a third immunization
with NYVAC- (Hel et al., 2001) or modified vaccinia
Ankara- (Hanke et al., 1999) based vaccine candidates.
Despite the immunogenicity of individual DNA or
Listeria vaccine approaches and their ability to induce a
cellular immune response, it was obvious that the HIV-1
antigen-specific immune response could be further
enhanced and it was possible that a prime boost strategy
would be a means of increasing the antigen-specific
cellular immune responses. DNA prime followed by a
boost with a recombinant live vector has the advantage of
enhancing passenger antigen-specific responses while
keeping the boosting of anti-vector responses to a
minimum. Prime/boost vaccine regimens have been shown
to be more effective than the individual vaccines for SIV
for DNA based vaccines combined with modified vaccinia
Ankara (Allen et al., 2000; Amara et al., 2001; Hanke et
al., 1999), NYVAC (Hel et al., 2001), and Salmonella
(Devico et al., 2002). In this paper, we show that DNA
primed and oral L. monocytogenes-boosted animals devel-
oped higher immune responses than either vaccine used
alone. Thus, 0.015% of total PBMCs were specific to
SIVmac239 Gag antigen and 0.014% of total PBMCs were
specific to SIVmac239 Gag antigen when rhesus macaques
were immunized with either DNA or L. monocytogenesrespectively. The immune responses, however, were in-
creased 4-fold such that 0.06% of total PBMCs were
specific to SIVmac239 Gag antigen in the animals primed
with DNA and boosted with L. monocytogenes. Similarly,
enhanced immune responses were observed to the Env
antigen when nonhuman primates were primed with the
DNA vaccine and boosted with the L. monocytogenes
vaccines. Clearly, a prime boost strategy that combines
these two vectors provides an immunological advantage
over either approach when used alone.
It has long been thought (Mackaness, 1962) that humoral
responses provide no resistance against listerial infections.
Antibody titers either in peripheral blood or in gut
associated lymphoid tissue are usually low in mice infected
by Listeria either parenterally or orally (Pan et al., 1995).
We also saw no increase in antibody titers against gp120
immediately after immunizing with Listeria either alone or
in a prime/boost combination. It is surprising, therefore, that
the animals that were immunized with Listeria alone clearly
demonstrated an anamnestic antibody response to SIV Env,
suggesting that priming by oral Listeria had taken place.
Despite the more rapid and higher antibody titers obtained
in this vaccine group, these did not appear to impact viral
replication or protection of circulating CD4+ T cell levels.
Only one of the DNA-primed and Listeria-boosted vacci-
nated macaques demonstrated an anamnestic antibody
response, macaque 3234. However, this group of macaques,
primed with DNA before boosting with recombinant
Listeria vaccine, had increased levels of SIV-specific
cellular immune responses prior to challenge and were able
Fig. 7. CD4+ Lymphocyte Counts following Challenge with SIV239. Samples were taken before and after SIV239 intrarectal challenge. PBMCs were isolated
and lymphocyte counts were assessed by standard assays and expressed as cell number per mm3. (A) Control animals, (B) animals immunized with L.
monocytogenes expressing Gag and Env DNA plasmids, and (C) animals immunized with pCSIVgag and pCSIVenv DNA plasmids followed by a boost with
the L. monocytogenes vaccines.
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lymphocytes.
This conclusion is consistent with a large number of
studies that have shown that the appearance of CTL in HIV
infection coincides with a marked decrease in plasma
viremia (Pantaleo et al., 1997) and there is a close inverse
correlation between viral load and levels of circulating HIV-
specific CTL (Ogg et al., 1998). The importance of HIV-
specific CTL in HIV infection gains further support from the
demonstration of HIV-specific CTL in highly exposed but
apparently uninfected individuals (Kaul et al., 2000; Row-
land-Jones et al., 1997). In this cohort study, an immune
response was found systemically but was enhanced in the
genital tract area at the likely site of virus exposure (Kaul et
al., 2000). Clearly, in future studies, it will be important for
us to measure the immune response to the DNA prime and
Listeria monocytogenes vaccines in the mucosa. Yet underany circumstances, it is still not clear what the correlate of
protection might be and whether we will be able to
determine unambiguously what will lead to protection from
SIV and subsequently HIV-1 infection or replication.
Although, the level of effector cells as assessed by ELISpot
may provide the best surrogate markers as to the level of
antigen-specific lymphocytes that are available to sequester
virus upon challenge.
We have not yet reached a level of protection that is
satisfactory. There is an obvious need to induce a higher
level of immune response that can suppress viral replication
in all challenged animals. In addition, we may need to
expand on the SIV genes included in our vaccines. Animal
3239 had a viral load that was suppressed below detectable
limits for approximately 16 weeks. The breakthrough
observed indicated that immune pressure did exist within
this animal and that the virus was most likely able to escape
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antigens demonstrate a swift immune escape phenomenon
(Vogel et al., 2003). A vaccine-elicited, single viral epitope-
specific cytotoxic T lymphocyte response does not protect
against intravenous, cell-free simian immunodeficiency
virus challenge, (Yasutomi et al., 1995). However, in this
paper, we have demonstrated the promise of these two
vaccines, as a combined strategy for an HIV vaccine and
their clear ability to induce an immune response that will
impact on mucosal challenge.Material and methods
Animals
Male and female Chinese rhesus macaques (Macaca
mulatta) 3 to 8 years old were evaluated at the start of the
study. The rhesus macaques were housed at Southern
Research Institute in Frederick, MD under USDA approved
conditions. These facilities are accredited by the American
Association for the Accreditation of Laboratory Animal
Care International and meet National Institute of Health
standards as set forth in the Guidelines for Care and Use of
Laboratory Animals.
Engineering and preparation of DNA plasmids
The pCSIVenv and the pCSIVgag plasmids expressing
the SIV envelope and core protein, Gag, are Rev-independ-
ent expression vectors that have been codon optimized for
high level expression as previously described (Nappi et al.,
2001). Codon optimization mutates the DNA sequence
without disrupting the amino acid sequence. Ultimately,
there is mutation or elimination of the RRE inhibitory
sequence, which leads to the more abundant translation of
tRNA. Plasmids were purified by Puresyn (Malvern, PA).
DNA was formulated in 0.15 M citrate buffer and 0.25%
bupivicaine at a pH of 6.5.
Recombinant Listeria monocytogenes constructs
The recombinant Listeria monocytogenes vaccines used
in this study are based on strain 10403S serotype 1 and carry
a single copy of each SIV strain 239 antigen gene stably
integrated into the listerial chromosome using a previously
described method of homologous recombination (Mata et
al., 2001). Lm-SIV-antigen strains were generated by
introducing the SIV genes directly into the L. monocyto-
genes chromosome under the control of the hly promoter
and including the hly signal sequence using plasmid pZY-
55, which is a modified shuttle vector pKSV7. The pKSV7
was modified by replacing its polylinker region with an
expression cassette containing a 1.6 KB EcoRI–HindIII
fragment containing a portion of the orfXYZ region of the
L. monocytogenes chromosome to provide a homologousregion for subsequent allelic exchange of the plasmid into
the chromosome and insertion of the genes into the orfZ
region of the listerial chromosome. To drive the expression
and secretion of the SIV gene products, a DNA fragment
containing a copy of the 288-nucleotide promoter sequence
of the L. monocytogenes hemolysin gene, signal sequence
and N-terminal cleavage site was introduced into a KpnI site
in the orf Z region. PCR primers were 5V-GGGGTA-
CCCTCCTTTGATTAGTATAT-3V (engineered KpnI site
underlined) and 5V-CCATACTATATGTTTTAATTTATT-
GAATGCAGATGCATC-3V. The orfXYZ fragment was
further modified by SOEing (gene Splicing by Overlap
Extension) PCR to include a multicloning site for the
insertion of foreign genes and a flag tag (GATTACAAG-
GATGACGACGATAAG) that encodes the sequence
DYKDDDDK, to facilitate the detection of the gene product
by Western blot.
To generate Lm-SIV-Gag the SIV gag gene was excised
from pCR2.1 by double digest with Bgl I and Nhe I and
ligated into pZY-55. The SIV gag gene was amplified by
PCR using the primers 5V-GGAGATCTTACATGTTGAAG-
CATGTAGTA-3V (engineered BglII site underlined) and 5V-
GGGCTAGCCTGGTCTCCTCCAAAGAGA-3V (engi-
neered NheI site underlined) and ligated into the BamHI
and XbaI cloning sites in the orfXYZ homology region of
pZY-55 downstream from the hly promoter and signal
sequence. L. monocytogenes strain 10403S was transformed
with pZY-55-SIV Gag. Clones were screened for integration
of the SIV gag gene cassette into the orfZ domain. The Gag
protein is expressed and secreted by Lm-SIV-Gag as
determined by Western blot with an anti-flag antibody.
Because of difficulties in expressing SIV env as a
secreted product, two SIV Env constructs were made that
together overlap the entire gp120 sequence. Lm-SIV-Env-5V
expresses the fragment residues 30 to 298 (omitting the
signal sequence) and includes domains I, II, and III of SIV
Env. This fragment was amplified from the env gene using
primers 5V-GGTCTAGATTAAGTCCTATTATCCCTACC-
3V (with engineered XbaI site underlined) and 5V-GG-
GGATCCGGTGTACCAGCTTGGAGG-3V (BamHI site
underlined) and ligated into the BamHI and XbaI cloning
sites in the orfXYZ homology region of pZY-55 down-
stream from the hly promoter and signal sequence. In a
similar manner Lm-SIV-3V was constructed that represents
residues 198 to 525 and encompasses domains III, IV and V
of the SIV gp120 polypeptide chain. The fragment was
amplified from the env gene using primers 5V-GGGGATCC-
TATTGGGATGCTATTAGA-3V (with engineered BamHI
site underlined) and 5V-GGTCTAGATCTTTTATTTCTT-
GAGGTGCC-3V (with engineered XbaI site underlined).
The secretion of polypeptide fragments of an appropriate
size was verified by Western blot.
Prior to their use, all strains of bacteria were mouse-
passaged in order to stabilize their behavior in vivo (28).
The bacteria were propagated on BHI (Difco, Detroit, MI).
Bacterial aliquots were stored at 70 8C. An inoculum of
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aliquot and appropriately diluting it in sterile PBS.
Immunization schedule and sample collection
Three groups of Chinese rhesus macaques were
immunized as outlined in Table 1. Four rhesus macaques
were immunized at weeks 0, 4, 8, and 12 with 2 mg each
of the pCSIVgag and pCSIVenv DNA plasmids. The
DNA immunizations were followed by three boosts with
recombinant L. monocytogenes at weeks 16, 20, and 28.
The L. monocytogenes was delivered orally as an equal
mixture of 1010 Lm-SIV-Gag and Lm-SIV-Env-5V and -3V
providing a total dose of 3  1010 bacteria for the first
two immunizations and 6  1010 bacteria/dose for the
final immunization. A second group of four rhesus
macaques received the L. monocytogenes delivered orally
as 3  1010 bacteria/dose for two immunizations and 6 
1010 bacteria/dose for the third immunization. Three
rhesus macaques remained naive as controls. Heparinized
blood was obtained for isolation of PBMCs and whole
blood was taken for sera samples. Samples were collected
prior to vaccination and 2 weeks after each injection.
PBMCs were isolated by a standard ficoll-hypaque
separation technique.
Peptides
One hundred and twenty five peptides corresponding to
the entire coding region SIVmac239 Gag protein and 212
peptides that encompassed SIVmac239 Env protein were
obtained from the AIDS Reagent Reference Repository
(NIH). These 15-mers overlapping by 11 amino acids were
resuspended in DMSO at a final concentration of 100 Ag/ml
and equal amounts of each peptide were mixed as one single
pool for Env and one for Gag for ELISpot analysis.
ELISpot assay
ELISpot was performed using IFN-g reagents from
MabTech (Sweden) and nitrocellulose plates, (Cellular
Technologies or Millipore). Briefly, plates were coated
with 7.5 Ag/mL IFN-g capture antibody and incubated
overnight at 4 8C or at room temperature for 2 h. After
washing with sterile PBS, the peptide pools (100 Ag/ml)
were diluted 1:200 in culture medium (RPMI 1640
containing 2 mM l-glutamine, 100 IU/ml penicillin and
100 IU/ml streptomycin) and 100 Al was transferred into
6 wells. The plates were sterilized by UV light for 15
min. Cells in culture media were added to the wells in
triplicate at a concentration of 200,000 cells per well. A
second set of PBMCs was depleted with anti-human CD8
depletion beads according to manufacturer’s protocol
(Dynal) before plating in triplicate. The plate was
incubated for 24 h at 37 8C, then washed with PBS.
Biotinylated antibody at a concentration of 1 Ag/ml wasadded and incubated overnight at 4 8C. After washing
streptavidin-AP was added at a concentration of 1 ng/ml
and incubated for 2 h at room temperature. Plates were
washed with PBS. BCIP/NBT was added and incubated in
the dark until spots appeared. The reaction was stopped
by rinsing several times with tap water. After drying, the
plates were scanned and counted using a Cellular
Technologies ELISpot reader. A positive response is
defined as 50 spot forming units (SFU) per million
PBMCs. The background observed in this study was
below 20 SFU per million PBMCs.
Anti-SIV antibody detection
Circulating anti-SIV antibodies were detected using an
HIV-2 ELISA (Genetic Systems, Seattle, Wash.) that is
cross-reactive for SIV antibodies. The ELISA used a fixed
plasma dilution of 1:200 and was run as directed using a
Vmax kinetic ELISA reader (Molecular Devices, Menlo
Park, CA). Values of optical density (OD) units minus
background were used as ELISA units.
Viral challenge
All animals were challenged intrarectally with 2500
TCID50 of SIV239 8 weeks after the last immunization.
Flow cytometry
Peripheral blood lymphocyte subset analysis was per-
formed on a FACS-scan flow cytometer (Becton-Dickinson,
Mountain View, CA) using a panel of mouse anti-human
monoclonal antibodies known to cross-react with macaque
receptors. The lymphocyte subsets were stained with CD-2
(T cells) (clone 39C1.5 FITC, Coulter, Miami, FL), CD-20
(Leu-16-PE, B cells) (Becton-Dickinson), CD-3 (SP34-PE,
Pharmagen, San Diego)/CD-4 (Leu-3a-FITC, Becton-Dic-
kinson) and CD-3/CD-8 (Leu-2a-PerCP, Becton-
Dickinson). CD4 cells as cell number per mm3 are reported.
Staining was performed on whole blood preparations.
Analysis was performed on lysed and paraformaldehyde-
fixed cells.
SIV viral RNA quantitation
SIV viral RNAwas quantitated in peripheral blood using a
previously described procedure (Suryanarayana et al., 1998).
500 Al of plasma was added to 1 ml of DPBS and spun for 1 h
at 10,000 RPM. The viral pellet was then lysed using
RNASTAT-60 (Tel-Test bBQ). The samples were then
amplified as previously described (Suryanarayana et al.,
1998), with the exception of the primers and probe. The
primers and probe used were SIV-F 5VAGTATGGGCAGCA-
AATGAAT 3V, SIV-R 5VTTCTCTTCTGCGTGAATGC 3V,
and the probe SIV-P 6FAMAGAT-TTGGATTAGCA-
GAAAGCCTGTTGGA-TAMRA. This assay has a nominal
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rayana et al., 1998).
Latent viral reservoirs
PBMC were isolated from heparinized blood using a
Percoll gradient centrifugation procedure. The resulting
PBMC were depleted of adherent cells and then depleted
of unwanted cell populations using monoclonal antibodies
and magnetic beads conjugated with anti-mouse IgG.
Therefore, our procedure used the following antibodies to
deplete unwanted cell populations: B cells, anti-CD20, NK
cells, anti-CD16, CD8+ T cells, anti-CD8, monocytes, anti-
CD14, activated CD4+ T cells, anti-CD25, anti-CD69, and
anti-HLA-DR. By staining cells with a cocktail of
antibodies to these markers followed by depletion with
anti-IgG-conjugated magnetic beads, we obtain populations
of CD4+ HLA-DR cells that are 80% pure. A subsequent
sorting step gives us N98% purity. Virus released from
latently infected cells was amplified by coculture of resting
CD4+ T cells with CEMx174 cells which are permissive
for high level replication of most SIV isolates including
the SIV239 strain were used. After 2–3 weeks of
coculture, supernatants were tested for the presence of
SIV p27 antigen by ELISA. Quantitation of latently
infected cells is achieved by setting the assay up in a
limiting dilution format. In addition to virus culture
approaches, molecular approaches for the detection of
cells in the post-integration stage of latency were used.
Primer hybridizing with conserved regions of Alu sequen-
ces were used together with an outward directed primer in
the SIV LTR to detect integrated SIV provirus in an
unambiguous way. This produced a band of a single size
from diverse integration sites. In each reaction, it was
critical to include a control in which the initial Alu–PCR is
run for zero cycles. This assured the bands obtained in the
nested reaction were dependent upon the initial integration-
dependent Alu–PCR reaction. Detection was dependent
upon the initial Alu–PCR reaction.
Detection of virus in inguinal lymph nodes by in situ
hybridization
Inguinal lymph nodes were harvested from macaques
after sacrifice 44 weeks following challenge with
SIV239. Formalin-fixed, paraffin-embedded tissues were
sectioned (4 to 5 mm thickness) and placed on DEPC
water-N-tris(hydromethyl) methyl-2-aminoethanesulfonic
acid (TES)-coated glass slides before being dried at
room temperature overnight. The slides were then heated
for 5 min and were then washed sequentially (twice for
5 min) in a mixture of xylene, 100% ethanol, 95%
ethanol, and DEPC-treated water. The slides were then
incubated with 5 mM levamisole for 20 min, 13 SSC
(13 SSC is 0.15 MNaCl plus 0.015 M sodium citrate)
for 2 min, and a solution containing 25 mg of proteinaseK per ml in 10 mM Tris (pH 7.4) and 0.2 mM CaCl2 at
37 8C for 10 min before further incubations in 0.1 M
glycine in PBS for 5 min, 13 PBS for 5 min, and
0.1 M triethanolamine  0.25% acetic anhydride for 10
min. Slides were prehybridized in prehybridization-hybrid-
ization buffer (50% formamide, 43 SSC, 13 Denhardt’s
solution, 4 mM NaPO4, 0.1% SDS, 5% dextran sulfate,
250 mg of tRNA per ml, 250 mg of salmon sperm DNA
per ml in DEPC water) in a preheated humidity chamber
under a coverslip for 15 min. The probe was added to the
hybridization buffer to a final concentration of 2.5 ng/ml,
and the slides were placed under coverslips, sealed with
rubber cement, heated to 65 8C for 5 min, chilled on ice,
and incubated overnight at 50 8C. Following hybridization,
the coverslips were removed and the sections were washed
in 23 SSC 50% formamide solution at 50 8C for 5 min
and then for 1 h, twice for 1 min in 23 SSC, and for 30
min in an RNase solution at 37 8C (RNase T1 and RNase
A in 23 SSC). These washing steps were repeated, and the
slides were blocked with a buffer containing 2% horse
serum, 0.3% Tween 20, 150 mM NaCl, and 100 mM Tris
(pH 7.4) for 1 h. Following the blocking, the slides were
incubated for 1 h with sheep antidigoxigenin alkaline
phosphatase conjugate at a 1:5,000 dilution in PBS  2%
horse serum, were washed twice, and were incubated with
nitroblue tetrazolium-5-bromo-4-chloro-3-indolylphosphate
toluidinium (NBT-BCIP) substrate in the dark at room
temperature for 2 h. The slides were counterstained with
nuclear fast red, dehydrated, and placed under coverslips.
Statistical analyses
Nonparametric statistics (Wilcoxon rank-sum test and
Friedman two way analysis of variance) were used to
compare antibody titers, CD4+ T cell counts and
ELISPOT data among control and vaccinated groups at
different time points. ELISPOT means before and after
CD8 depletion were examined for statistical differences
using the Wilcoxon signed-rank test for paired data.
Comparisons among proportions were done using Fisher
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